Takeda Gets Actos Case Paused For Class Cert. Review

By Matthew Perlman · April 14, 2025, 3:55 PM EDT

A New York federal court has paused a lawsuit accusing Takeda Pharmaceuticals of inflating the price of its diabetes treatment, Actos, by delaying the entry of generic alternatives, and took a...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

In re ACTOS Antitrust Litigation

Case Number

1:13-cv-09244

Court

New York Southern

Nature of Suit

Contract: Other

Date Filed

December 31, 2013

Case Title

In Re: ACTOS Antitrust Litigation

Case Number

24-2749

Court

Appellate - 2nd Circuit

Nature of Suit

Date Filed

October 18, 2024

Recent Articles By Matthew

April 07, 2025
Monthly Merger Review Snapshot
April 02, 2025
Serial Acquisitions Are Still On The FTC's Radar
April 01, 2025
Takeda Antitrust Trial Over Actos Generics Set For July
March 28, 2025
PE Firm Hits Back Against Medical Device Coating Challenge
March 27, 2025
DOJ's Antitrust Unit Targeting Anticompetitive Regulations
March 20, 2025
8th Circ. Won't Pause FTC's Insulin Pricing Case
March 17, 2025
Court Won't Toss Biotech Co.'s Antitrust Counterclaim
March 14, 2025
FTC Urges 8th Circ. Not To Pause Insulin Pricing Case
March 13, 2025
Calif. AG Appealing State Limits On Pay-For-Delay Ban
March 12, 2025
4th Circ. Won't Undo Health Data Access Order

Takeda Gets Actos Case Paused For Class Cert. Review

Documents

Related Sections

Case Information

Case Title

Case Number

Court

Nature of Suit

Date Filed

Case Title

Case Number

Court

Nature of Suit

Date Filed

Recent Articles By Matthew